Loading clinical trials...
Loading clinical trials...
A Phase 1b Study of Serabelisib in Combination With an Insulin Suppressing Diet (Study ISD) and With or Without Nab-paclitaxel in Adult Subjects With Advanced Solid Tumors With PIK3CA Mutations With or Without PTEN Loss
Conditions
Interventions
Serabelisib
Insulin Suppressing Diet
+1 more
Locations
17
United States
University of Alabama
Birmingham, Alabama, United States
Pacific Cancer Specialists
Anaheim, California, United States
Valkyrie Clinical Trials
Los Angeles, California, United States
Hoag Memorial Hospital Presbyterian
Newport Beach, California, United States
Community Health Network, Inc.
Indianapolis, Indiana, United States
Mayo Clinic - Rochester
Rochester, Minnesota, United States
Start Date
April 22, 2022
Primary Completion Date
April 30, 2025
Completion Date
April 30, 2025
Last Updated
October 6, 2025
NCT07177937
NCT05919264
NCT07181681
NCT07387068
NCT06257264
NCT07360314
Lead Sponsor
Faeth Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions